AIM ImmunoTech Inc.

AIM

US00901B3033

Biotechnology & Medical Research

Delayed Nyse Other stock markets 10:24:30 2026-04-16 am EDT			5-day change	1st Jan Change
0.5548 ^USD	+1.68%		+7.12%	-50.85%

Apr. 13	Aim ImmunoTech provides routine update on annual filings	RE
Mar. 27	AIM ImmunoTech Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

AIM ImmunoTech signs agreement for planning of a proposed Phase 3 clinical trial of Ampligen in the treatment of late-stage pancreatic cancer

Published on 03/02/2026 at 09:41 am EST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about AIM ImmunoTech Inc.

Apr. 13	Aim ImmunoTech provides routine update on annual filings	RE
Mar. 27	AIM ImmunoTech Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Mar. 26	AIM ImmunoTech Inc. Auditor Raises 'Going Concern' Doubt	CI
Mar. 18	AIM ImmunoTech Inc Announces Final Approval Of Novel Cancer Therapy Patent In Japan Combining Ampligen With Checkpoint Inhibitors	CI
Mar. 18	AIM ImmunoTech announces final approval of novel cancer therapy patent in Japan combining Ampligen with checkpoint inhibitors	RE
Mar. 04	Aim ImmunoTech announces expiration and preliminary results of its rights offering for aggregate gross proceeds of $1.8 million	RE
Mar. 02	AIM ImmunoTech signs agreement for planning of a proposed Phase 3 clinical trial of Ampligen in the treatment of late-stage pancreatic cancer	RE
Mar. 02	AIM ImmunoTech Signs Agreement for Planning of A Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer	CI
Feb. 25	Aim Immunotech announces extension of subscription period	RE
Feb. 23	Aim Immunotech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and Astrazeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer	CI
Feb. 11	AIM ImmunoTech announces commencement of rights offering	RE
Feb. 05	Aim Immunotech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen®? (Rintatolimod) in Combination with Astrazeneca's Imfinzi®? for the Treatment of Pancreatic Cancer	CI
Feb. 05	AIM ImmunoTech reports year-end positive phase 2 interim progress for Ampligen® (rintatolimod) plus AstraZeneca's Imfinzi® (durvalumab) in pancreatic cancer	RE
Jan. 23	AIM ImmunoTech Files Preliminary Prospectus for Rights Offering	MT
Jan. 23	AIM ImmunoTech Stock Trading Halted, Pending Material News Release	MT

AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.

Employees

Sector

Biotechnology & Medical Research

More about the company